What Is Aleniglipron?

1. What Kind of Drug Is Aleniglipron?

Aleniglipron is a non-peptide small molecule that activates the GLP-1 receptor, a pathway that reduces appetite and increases fullness (ACCESS paper). It started as a capsule and became a once-daily tablet during Phase 2a (Phase 2a announcement).

Unlike most late-stage oral GLP-1 candidates, it was not licensed in from another company. Structure Therapeutics, founded by the structural biologist Raymond Stevens, designed it using the company’s structure-based discovery platform, and describes it as a biased agonist that favors the G-protein signaling pathway at the receptor (Phase 2a announcement, September 2026 update). Whether that design translates into better tolerability is a claim the trials have to prove.

Like orforglipron, it is an oral small molecule; oral semaglutide is a peptide formulated for absorption. Orforglipron is already marketed as Foundayo, and elecoglipron and HRS-7535 are on similar timelines to aleniglipron. All of aleniglipron’s trials have compared it with placebo, so they do not establish that it works better than any of these.

2. What Did the Core ACCESS Trial Show?

At 36 weeks the 120 mg arm lost 12.1% of body weight against 0.8% on placebo, a placebo-adjusted difference of 11.3 points. ACCESS was a randomized, double-blind, placebo-controlled Phase 2b study of 230 adults without diabetes who had obesity, or overweight plus a weight-related condition. The group was heavier than in many obesity trials, with a mean BMI of 39.5, and the dose was stepped up every four weeks to a target of 45, 90 or 120 mg (December 2025 ACCESS report, PubMed abstract).

The placebo-adjusted results were 8.2, 9.8 and 11.3 points for the 45, 90 and 120 mg arms, all highly significant, and the paper reports no apparent plateau at the end of the 36 weeks. The efficacy estimand estimates the effect if participants completed treatment; an analysis that counted outcomes regardless of adherence gave 11.4% in the 120 mg arm (peer-reviewed ACCESS publication).

The ACCESS open-label extension reported continued weight loss through 56 weeks (extension update), and Structure announced the final 72-week results on September 8, 2026. Participants originally assigned to 45, 90 and 120 mg, who were stepped up to as much as 180 mg from about week 60, had lost 11.6%, 14.4% and 16.2% at 72 weeks; the 16.2% matches the figure Structure reported for the 120 mg group at the 56-week interim. Former placebo participants who switched to aleniglipron at week 36 lost 9.0% after 36 weeks of treatment. All continuing participants received aleniglipron, so this longer follow-up had no parallel placebo comparison, and the results are a company announcement, not yet peer-reviewed (September 2026 extension results).

3. Where Does the 16.3% Weight-Loss Figure Come From?

The 16.3% placebo-adjusted figure comes from the separate ACCESS II study at 44 weeks. In the 180 mg research group, mean weight fell 15.3%, while placebo gained 1.1%; Structure reports the difference as 16.3%, or about 39 pounds. A 240 mg group reached 16.0%, so the highest dose added nothing over 180 mg (March 2026 ACCESS II results).

Treat that number with care. ACCESS II enrolled 85 people, and the 44-week figures come from participants who were re-randomized after an initial treatment period into groups of just 8, 10 and 9 on active doses and 10 on placebo. They had already tolerated the drug for 28 weeks, so the result describes people who stayed on treatment rather than everyone who starts it (ADA trial poster). The upside of that design is a tolerability signal: among participants who reached 120 mg or more, only one person, 3.7%, stopped for side effects between weeks 28 and 44.

4. What Side Effects Were Reported?

Nausea and vomiting were the prominent events during escalation. Across active arms in core ACCESS, 10.4% stopped treatment because of adverse events, most of them early. The Nature Medicine paper describes gastrointestinal events as generally mild to moderate and decreasing over time, and notes that when participants paused the drug under the protocol and then restarted, vomiting rarely recurred (ACCESS paper, June publication update).

Structure’s answer to the early dropouts is a gentler start. In the open-label extension, former placebo participants began at 2.5 mg rather than the 5 mg starting dose used in the core trial. In the 72-week results, Structure reported better gastrointestinal tolerability with that start, fewer than 5% of extension participants stopping for adverse events, and no drug-induced liver injury. The Phase 3 trials now use the 2.5 mg start, so ACCOMPLISH will be the real test (September 2026 extension results).

The paper reports no drug-induced liver injury during the randomized period. Larger, longer trials are still needed to assess uncommon harms.

5. What Is the Phase 3 and Approval Timeline?

The two pivotal studies address different populations:

Structure announced first-patient dosing on August 6, 2026; the registry lists both studies as starting in July 2026. Both studies are randomized, double-blind and placebo-controlled, and compare three maintenance doses, 45, 90 or 180 mg, with placebo after a 2.5 mg start and four-weekly dose steps. They are designed to support global regulatory submissions (Phase 3 announcement). Structure expects topline data in the second half of 2028, and the registry lists estimated primary completion in September 2028 (September 2026 update, ACCOMPLISH-1 registry).

There is no confirmed release date. These milestones were checked October 15, 2026:

The late-2026 windows are sponsor forecasts for supplementary studies, not Phase 3 results. Two of them matter beyond aleniglipron itself. The body-composition study measures fat loss over 44 weeks, addressing the concern that GLP-1 drugs shed muscle along with fat. SWITCH tests whether people who have lost weight on an approved injectable GLP-1 can move to the tablet and keep the weight off, which is the use case Structure is building its commercial plan around (Structure’s August update, September update).

6. How Does It Fit Among Oral GLP-1 Tablets?

ACCESS II’s 16.3 points is the highest Phase 2 figure among the small-molecule tablets still in development, which is why Structure calls it potentially best in class. At 36 weeks, though, core ACCESS’s 11.3 points is close to elecoglipron’s roughly 11.5. The caveat is the usual one: these are different trials with different populations, durations and analysis methods, and ACCESS II’s 16.3% came from a few dozen re-randomized people. Only ACCOMPLISH, with thousands of participants over a longer period, can show whether the advantage is real. Structure is also pairing aleniglipron with an oral amylin agonist, ACCG-2671, which added weight loss to aleniglipron in non-human primates; a combination trial is planned for late 2026 (August 2026 update). In its first human study, single doses in 31 healthy volunteers were reported in September 2026, and a 12-week multiple-dose study is under way, so there are no human combination data yet (September 2026 update).

7. Aleniglipron FAQ

• Is aleniglipron the same as GSBR-1290?

  Yes. GSBR-1290 is the development code Structure used until the generic name was assigned; older trial listings and the 2024 Phase 2a results still use it.

• Is aleniglipron FDA-approved or available to prescribe?

  No. As of October 15, 2026, aleniglipron is investigational, with Phase 3 ACCOMPLISH underway and no confirmed launch date. Structure expects Phase 3 topline data in the second half of 2028, and a filing can only follow that readout, so an approval before 2029 would be unusual.

• How much weight loss did aleniglipron produce?

  Core ACCESS reported 12.1% mean weight loss versus 0.8% with placebo at 36 weeks on 120 mg, or 11.3 points placebo-adjusted. ACCESS II reported 16.3 points placebo-adjusted at 44 weeks on 180 mg. Longer treatment and a higher dose explain most of the gap, not a different drug.

• Does aleniglipron cause nausea?

  Nausea and vomiting were common during dose escalation, and 10.4% of people on active doses in core ACCESS stopped for side effects. The trial paper notes that vomiting rarely came back after a permitted dose pause. In the extension study, a gentler start at 2.5 mg improved tolerability, and the Phase 3 trials use that start.

• Is aleniglipron better than semaglutide or orforglipron?

  Unknown. Every aleniglipron trial so far compared it with placebo. The SWITCH study will test whether people can move from an injectable GLP-1 to the tablet without regaining weight, which is a different question from head-to-head efficacy.

8. Sources